116 related articles for article (PubMed ID: 20576295)
21. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
[TBL] [Abstract][Full Text] [Related]
22. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Mirick GR; DeNardo SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
[TBL] [Abstract][Full Text] [Related]
23. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
24. Canine CD20 gene.
Kano R; Inoiue C; Okano H; Yamazaki J; Takahashi T; Watari T; Tokuriki M; Hasegawa A
Vet Immunol Immunopathol; 2005 Dec; 108(3-4):265-8. PubMed ID: 16061290
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody SN10 which shows a highly selective reactivity with human B leukemia-lymphoma and is effectively internalized into cells.
Takeuchi T; Barcos MP; Seon BK
Cancer Res; 1991 Jun; 51(11):2985-93. PubMed ID: 1709587
[TBL] [Abstract][Full Text] [Related]
26. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
27. Two monoclonal antibodies defining unique antigenic determinants on human B-lymphoma cells.
Howard DR; Eaves AC; Takei F
Cancer Res; 1985 Dec; 45(12 Pt 1):6322-7. PubMed ID: 2415242
[TBL] [Abstract][Full Text] [Related]
28. Histologic classification and immunophenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T cell lymphomas with B cell morphology.
Teske E; Wisman P; Moore PF; van Heerde P
Exp Hematol; 1994 Nov; 22(12):1179-87. PubMed ID: 7925781
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical staining of non-Hodgkin's lymphoma with monoclonal antibodies specific for the leucocyte common antigen.
Salter DM; Krajewski AS; Dewar AE
J Pathol; 1985 Aug; 146(4):345-53. PubMed ID: 2411901
[TBL] [Abstract][Full Text] [Related]
30. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
DeNardo GL; Tobin E; Chan K; Bradt BM; DeNardo SJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7075s-7079s. PubMed ID: 16203805
[TBL] [Abstract][Full Text] [Related]
31. Generation and Validation of an Antibody to Canine CD19 for Diagnostic and Future Therapeutic Purposes.
Haran KP; Lockhart A; Xiong A; Radaelli E; Savickas PJ; Posey A; Mason NJ
Vet Pathol; 2020 Mar; 57(2):241-252. PubMed ID: 32081102
[TBL] [Abstract][Full Text] [Related]
32. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.
Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK
Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458
[TBL] [Abstract][Full Text] [Related]
33. Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping.
Guija de Arespacochaga A; Schwendenwein I; Weissenböck H
J Comp Pathol; 2007; 136(2-3):186-92. PubMed ID: 17416237
[TBL] [Abstract][Full Text] [Related]
34. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen.
Kreipe H; Wacker HH; Heidebrecht HJ; Haas K; Hauberg M; Tiemann M; Parwaresch R
Am J Pathol; 1993 Jun; 142(6):1689-94. PubMed ID: 7685150
[TBL] [Abstract][Full Text] [Related]
35. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.
Carbone A; Gloghini A; Gruss HJ; Pinto A
Am J Pathol; 1995 Oct; 147(4):912-22. PubMed ID: 7573367
[TBL] [Abstract][Full Text] [Related]
36. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical analysis of human MHC class II antigens in B-cell non-Hodgkin's lymphomas.
Krajewski AS; Guy K; Dewar AE; Cossar D
J Pathol; 1985 Feb; 145(2):185-94. PubMed ID: 2579225
[TBL] [Abstract][Full Text] [Related]
38. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
39. Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma.
Nowak J; Kalinka-Warzocha E; Juszczynski P; Bilinski P; Mika-Witkowska R; Zajko M; Bienvenu J; Coiffier B; Salles G; Warzocha K
Genes Chromosomes Cancer; 2007 May; 46(5):500-7. PubMed ID: 17311253
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
